

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is true about the design of the Phase II KarMMa trial, which demonstrated high response rates with the B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell construct idecabtagene vicleucel (ide-cel) for patients with multiple myeloma (MM)?**
 - a. The trial was for patients with newly diagnosed MM only
 - b. The trial was for patients with heavily pretreated MM only**
 - c. The trial included patients with newly diagnosed and relapsed/refractory (R/R) MM
- 2. Results from the Phase Ib/II CARTITUDE-1 trial evaluating the BCMA-directed CAR T-cell construct ciltacabtagene autoleucel (cilta-cel) for R/R MM included which of the following outcomes?**
 - a. Deep responses and durable progression-free survival for patients with heavily pretreated disease**
 - b. Short-lived responses and poorer progression-free survival for patients with heavily pretreated disease
- 3. Which of the following statements is true regarding the structures of ide-cel and cilta-cel?**
 - a. Cilta-cel has 2 BCMA-targeted binding domains**
 - b. Ide-cel has 2 BCMA-targeted binding domains
 - c. Both ide-cel and cilta-cel have 1 BCMA-targeted binding domain
- 4. Which of the following comparisons to the CARTITUDE-1 trial accurately reflects safety results from the Phase II CARTITUDE-2 trial assessing cilta-cel for patients with R/R MM?**
 - a. Incidence of delayed neurotoxicity was similar in both trials
 - b. Incidence of delayed neurotoxicity was higher in CARTITUDE-2
 - c. Incidence of delayed neurotoxicity was lower in CARTITUDE-2**